Digital Therapeutics for Respiratory Diseases Market Size (2023 - 2030):

Global Digital Therapeutics for Respiratory Diseases Market is estimated to be worth USD 755.71 Million in 2022 and is projected to reach a value of USD 4831.43 Million by 2030, growing at a CAGR of 26.1% during the forecast period 2023-2030.

Software-based interventions known as digital therapeutics (DTx) strive to prevent, manage, and treat health conditions. These patient-focused applications have proven clinical benefits and help individuals improve their quality of life by managing symptoms on their own. DTx utilizes digital tools like mobile devices, apps, sensors, virtual reality, and IoT to foster behavior changes in patients. They can be utilized as standalone treatments or in combination with conventional approaches, relying on digital data analysis for monitoring progress and preventing further complications. DTx is an emerging sector within digital health, with breakthroughs developed for ailments such as diabetes, heart failure, Alzheimer's, anxiety, and depression. The benefits of digital therapeutics include convenient health management from home, personalized treatment plans, and cost savings. With digital therapeutics, patients can easily access healthcare services without the need for travel, co-pays, or time off work. The personalized treatment plans offered by digital therapeutics apps adapt to individual needs based on collected data, resulting in better outcomes. Additionally, digital therapeutics are more affordable as they typically operate on a subscription-based model, eliminating expenses for office visits, unnecessary medications, and travel. In some cases, health insurance or employers may cover the costs of digital therapeutics, further reducing financial burdens for patients.

Global Digital Therapeutics for Respiratory Diseases Market Drivers:

The rising incidence of respiratory diseases is fueling the growth of the global digital therapeutics for respiratory diseases market.

The two most prevalent chronic respiratory disorders that negatively impact the passageways in the lungs are asthma and chronic obstructive pulmonary disease (COPD). Asthma is defined by repeated shortness of breath and wheezing caused by constricted passageways, with symptoms ranging in severity and frequency. It is prevalent among children and can be managed with inhaled medications. In contrast, COPD primarily affects adults and is associated with irreversible airway obstruction, causing breathlessness, sputum production, and chronic cough. Air pollution, allergies, occupational risks, and tobacco utilization are risk factors for various illnesses. In 2019, CRDs accounted for a total of 534,242 deaths in the Americas, with an equal number of deaths in both sexes (267,516 in men and 266,725 in women). The age-standardized mortality rate was 35.8 deaths per 100,000 population, with a higher rate observed in men (42.2 deaths per 100,000) contrasted to women (31.0 deaths per 100,000). These findings emphasize the substantial influence of CRDs on mortality rates in the Americas, particularly among men. Therefore, this factor drives the demand for digital therapeutics for respiratory diseases.

The improved access to healthcare services in remote areas is another factor contributing to the growth of the global digital therapeutics for respiratory diseases market.

In certain geographically distant and remote locations, or after a natural disaster, accessing consistent healthcare services is a challenge. However, with the advent of digital therapeutic solutions, emergency medical care can be provided. This innovative technology is particularly useful for patients living in remote locations that are difficult to access. Instead of having to undertake a strenuous journey to reach a hospital, digital therapeutic solutions allow patients to receive clinical healthcare services from the comfort of their own homes. Indeed, this technology has been an invaluable resource for individuals who would otherwise not have access to medical care. Therefore, this factor also drives the demand for digital therapeutics for respiratory diseases.

Global Digital Therapeutics for Respiratory Diseases Market Challenges:

The global digital therapeutics for respiratory diseases market is encountering challenges, primarily in terms of assuring patient data privacy and security in complex digital therapeutics systems. Continuous monitoring and analysis of patient data within a complex digital system can raise concerns about constant surveillance and the potential misuse of personal profiles. The processing of highly sensitive data in DTx applications makes data breaches a significant threat, with potentially severe consequences for individuals. The utilization of multiple operating systems and application providers in the DTx ecosystem adds complexity, which can lead to security vulnerabilities. These vulnerabilities increase the risk of unauthorized access and breaches across devices and providers, posing a potential danger to patient data privacy and security. Thus, these challenges inhibit the growth of the global digital therapeutics for respiratory diseases market.

Global Digital Therapeutics for Respiratory Diseases Market Opportunities:

Technology advancements present a lucrative opportunity in the global digital therapeutics for respiratory diseases market. Given the rising demand for digital therapeutics for respiratory diseases owing to its advantages, including improved access to healthcare, enhanced patient engagement, improved patient outcomes, and reduced patient expenses, businesses specializing in digital therapeutic solutions can stand to gain significantly from this opportunity by incorporating cutting-edge technologies, including AI and ML in digital therapeutic solutions, and enhanced sensor technology in healthcare devices, allowing for capturing more accurate and extensive health data and will enable the delivery of more individualized insights and recommendations based on patient's health data. This could potentially result in more accurate diagnoses, early detection of respiratory illnesses, and better treatment recommendations.

COVID-19 Impact on the Global Digital Therapeutics for Respiratory Diseases Market:

The outbreak of the COVID-19 pandemic substantially impacted the global digital therapeutics for respiratory diseases market. The implementation of strict lockdowns, traveling restrictions, and social distancing measures across several nations hindered many companies' manufacturing capacities and caused a shortage of skilled workforce. The pandemic caused disruptions in supply chains and distribution of goods and services, which highly affected the deployment of digital therapeutic solutions. This factor negatively impacted the growth of the global digital therapeutics for respiratory diseases market. However, as patients sought ways to monitor their health from home and communicate with healthcare practitioners remotely, the pandemic accelerated the adoption of digital therapeutic solutions, which helped to prevent disease exacerbations and reduce the need for in-person visits. This factor positively impacted the market's growth. Therefore, the global digital therapeutics for respiratory diseases market experienced both challenges and opportunities during the difficult time of the COVID-19 pandemic.

Global Digital Therapeutics for Respiratory Diseases Market Recent Developments:

• In December 2022, Life Semantics Corp. unveiled Redpill Breath, a digital therapeutics solution targeting pulmonary rehabilitation for patients, including those with chronic obstructive pulmonary disease (COPD). They aim to expand its availability internationally, gaining insights into global digital therapeutics trends and assessing global demand. 

• In July 2022, VisionHealth and Boehringer Ingelheim joined forces to develop the Kata® app, a Class II medical device devised to support therapy for asthma and chronic obstructive pulmonary disease (COPD). This collaboration aims to address the crucial need for accurate inhaler usage, as studies indicate error rates ranging from 32% to 100%. By providing targeted inhalation support, the app can help individuals with chronic respiratory diseases ensure they receive the correct dosage of medication, potentially preventing disease progression. 

• In November 2020, Kaia Health and Chiesi partnered to bring the Kaia Health COPD Pulmonary Rehabilitation app to Europe. This collaboration is notable as it marks a rare instance in respiratory care where a digital therapeutics and pharmaceutical company join forces to provide patients with a digital therapeutic solution. The app emphasizes behavior change to support COPD treatment outcomes, offering an alternative approach to medication-based treatment. Their exclusive partnership aims to commercialize the app and make it widely available across Europe.

DIGITAL THERAPEUTICS FOR RESPIRATORY DISEASES MARKET REPORT COVERAGE:

Global Digital Therapeutics for Respiratory Diseases Market Segmentation: By Type

• Devices

  • Handheld Devices

  • Portable Devices

  • Wearable Devices

• Software and Services

The market for digital therapeutics devices for respiratory disease is rising significantly as a result of the increasing use of digital health solutions and the rising incidence of chronic diseases. Technology advances, heightened public awareness of the advantages of digital therapies, and the expanding demand for remote monitoring and self-management of medical issues are some of the reasons driving the market. Due to its popularity and extensive use in health and wellness applications, wearable technology now has the biggest market share. However, due to their ease and the growing number of healthcare applications, handheld and portable devices are gaining popularity.

Global Digital Therapeutics for Respiratory Diseases Market Segmentation: By Disease Type

• Asthma

• Chronic Obstructive Pulmonary Disease (COPD)

• Pulmonary Fibrosis

• Pneumonia

• Lung Cancer

• Others

In 2022, the COPD segment held the highest market share. The growth can be ascribed to COPD being the most prevalent respiratory illness and the 3rd largest cause of mortality globally, accounting for 3.23 million deaths in 2019. Low- and middle-income countries (LMICs) account for about 90% of COPD fatalities among those under the age of 70. According to disability-adjusted life years (DALYs), COPD is the 7th largest contributor to poor health globally. Companies like KAMU Health Ltd., ResMed Inc., and Kaia Health have developed digital therapeutic solutions specifically for COPD patients. These solutions provide tools for tracking medication usage, monitoring symptoms, and accessing personalized information on disease management. This technology plays a vital role in supporting COPD patients and enhancing their overall care by empowering both patients and healthcare providers with valuable insights and resources.

Global Digital Therapeutics for Respiratory Diseases Market Segmentation: By End-User

• Providers

• Patients

• Payers

In 2022, the provider segment held the highest market share. The growth can be attributed to the rising adoption of digital therapeutics among healthcare providers to lower the burden on healthcare facilities. Digital therapeutic solutions enhance the convenience of healthcare providers by allowing them to access patient health records quickly and easily, as well as offer real-time quality reporting, improved data management, and improved decision-making.

Global Digital Therapeutics for Respiratory Diseases Market Segmentation: By Region

• North America

• Europe

• Asia-Pacific

• South America

• Middle East & Africa

The region of North America held the largest share of the global digital therapeutics for respiratory diseases market in the year 2022. The rising incidence of respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, pneumonia, and lung cancer, the presence of well-established healthcare industries in nations, such as the United States and Canada, and the early and wide adoption of advanced healthcare technologies are some of the factors propelling the region's growth. Additionally, North America is home to several significant market players, including ResMed Inc., AptarGroup, Inc., NuvoAir US, Inc., Kaia Health, and HealthSnap, Inc. Due to the presence of well-established healthcare industries in nations, such as Germany, the United Kingdom, and France, the increasing prevalence of respiratory diseases, the growing technological advancements in healthcare industries, and the strong presence of major market players, including KAMU Health Ltd., VisionHealth, and my mHealth Limited, the region of Europe are anticipated to expand at the quickest rate over the forecast period.

Global Digital Therapeutics for Respiratory Diseases Market Key Players:

1. ResMed Inc. (United States)

2. KAMU Health Ltd. (Finland)

3. AptarGroup, Inc. (United States)

4. NuvoAir US, Inc. (United States)

5. VisionHealth (Germany)

6. Life Semantics Corp. (South Korea)

7. my mHealth Limited (United Kingdom)

8. Kaia Health (United States)

9. Respiree Pte Ltd. (Singapore)

10. HealthSnap, Inc. (United States)